{"entity":{"id":"cancerdetect-imbdx","kind":"drug","name":"CancerDetect","aka":["IMBdx CancerDetect","AlphaLiquid Detect"],"tldr":"IMBdx's personalised blood test for leftover cancer, from Seoul, which adds a set of common treatable mutations to the patient's own.","summary":"CancerDetect, formerly reported as AlphaLiquid Detect, is the residual disease test of IMBdx of Seoul. Its analytical validation (Heo et al., PLoS One 2025) combines personalised mutations with tumour-agnostic hotspot mutations and reports a limit of detection of 0.001 per cent with 99.9 per cent specificity. The full text measured that limit on a cell-line mixture of 385 germline single-nucleotide polymorphisms rather than on tumour mutations, and the hotspot regions had a separate limit of 0.1 per cent.","status":"emerging","asOf":"2026-11-04","links":[{"label":"Heo et al., analytical validation of CancerDetect (PLoS One 2025)","url":"https://doi.org/10.1371/journal.pone.0334282"}],"tags":["test","mrd"],"related":[],"cancers":[],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":["imbdx"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-heo-cancerdetect-validation-plos-one-2025"],"journals":[],"dependsOn":[],"notes":["Stated limit of detection, in the abstract's words: \"limit of detection successfully reached down to 0.001% (10-5) with 99.9% specificity\" (Heo et al., PLoS One 2025). That is 10 parts per million, at rather than below that level, on a germline-variant mixture."],"brand":"CancerDetect","modality":"Tumour-informed ctDNA minimal residual disease test (bespoke variants plus hotspot panel, hybrid capture)","mechanism":"A bespoke capture panel of patient-specific mutations from tumour sequencing, combined with tumour-agnostic actionable hotspot targets, read with molecular barcodes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cancerdetect-imbdx/","neighbours":{"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"imbdx","kind":"company","name":"IMBdx","route":"/companies/imbdx/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}],"paper":[{"id":"paper-heo-cancerdetect-validation-plos-one-2025","kind":"paper","name":"Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease","route":"/key-papers/paper-heo-cancerdetect-validation-plos-one-2025/"}]}}